Investors

Envista Reports Fourth Quarter 2020 Results

BREA, Calif., Feb. 10, 2021 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the fourth quarter 2020.

For the fourth quarter, the Company's net income was $108.4 million, or $0.64 per diluted share. For the same period, adjusted net income was $94.6 million, or $0.56 per diluted share. Adjusted EBITDA for the three months ended December 31, 2020 was $150.8 million, a 23.1% increase compared to $122.5 million for the comparable period in 2019.

Sales for the fourth quarter of 2020 were $732.3 million, an increase of 1.6% as compared to the same period year-over-year. Core sales increased 3.4% over the same period in the prior year.

Operating cash flow for the fourth quarter of 2020 was $193.4 million, an increase of 3.4% as compared to the same period year-over-year. Free cash flow was $185.6 million, an increase of 8.5% compared to the fourth quarter of 2019. In February, Envista repaid $472 million of bank term debt and amended its credit agreement to reinstate most of the original terms.

Amir Aghdaei, Chief Executive Officer, stated, "We delivered outstanding fourth quarter results with 3.4% core sales growth, an 8.5% increase in free cash flow, and a 23% increase in adjusted EBITDA. We are proud of our team's dedication to building a company that provides customers and partners with the products and support they need to improve the productivity and predictability of care for their patients." 

Mr. Aghdaei continued, "Our commitment to continuous improvement, powered by the Envista Business System, has been the driving force behind accelerating growth in our Specialty and Infection Prevention businesses while allowing us to significantly improve our operational capabilities and reduce our structural footprint. With the demonstrable progress on these strategic initiatives combined with an improved portfolio and balance sheet, we believe Envista is stronger than ever entering 2021 and positioned well for enhanced performance."

Envista will discuss its results during a quarterly investor conference call today starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Envista's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 866-648-5306 within the U.S. or by dialing +1 602-563-8479 outside the U.S. a few minutes before the 2:00 P.M. PT start and referencing conference ID # 4980251. A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of Envista's website under the subheading "Events & Presentations." In addition, presentation materials relating to Envista's results have been posted to the "Investors" section of Envista's website under the subheading "Quarterly Earnings."

ABOUT ENVISTA

Envista is a global family of more than 30 trusted dental brands, united by a shared purpose: to partner with professionals to improve lives.  Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.  Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers an estimated 90% of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile.  Envista companies, including KaVo Kerr, Nobel Biocare, and Ormco, partner with dental professionals to help them deliver the best possible patient care.  With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in customer centricity, commitment to innovation, respect, continuous improvement, and leadership, Envista is well-equipped to meet the end-to-end needs of dental professionals worldwide.  Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.  For more information, please visit www.envistaco.com.

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules.

FORWARD-LOOKING STATEMENTS

Certain statements in this release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, the conditions in the U.S. and global economy, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, significant restrictions and/or potential liability based on tax implications of transactions with Danaher, security breaches or other disruptions of our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors,  and disruptions relating to war, terrorism, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2019 and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

CONTACT

John Bedford
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, California 92821
Telephone: (714) 817-7000

 

ENVISTA HOLDINGS CORPORATION
CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (UNAUDITED)
($ and shares in millions, except per share amounts)



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Sales

$

732.3



$

720.5



$

2,282.0



$

2,751.6


Cost of sales

343.8



331.1



1,123.9



1,238.5


Gross profit

388.5



389.4



1,158.1



1,513.1


Operating expenses:








Selling, general and administrative

264.6



276.0



1,024.0



1,080.9


Research and development

27.1



35.4



100.8



154.7


Operating profit

96.8



78.0



33.3



277.5


Nonoperating (expense) income:








Other (expense) income

(1.3)



(0.1)



(0.9)



1.5


Interest expense, net

(21.3)



(3.3)



(62.5)



(3.5)


Income (loss) before income taxes

74.2



74.6



(30.1)



275.5


Income tax (benefit) expense

(34.2)



18.5



(63.4)



57.9


Net income

$

108.4



$

56.1



$

33.3



$

217.6


Earnings per share:








Basic

$

0.68



$

0.35



$

0.21



$

1.60


Diluted

$

0.64



$

0.35



$

0.20



$

1.60


Average common stock and common equivalent
shares outstanding:








Basic

160.0



158.7



159.6



136.2


Diluted

170.0



159.3



164.1



136.4


 

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
($ in millions, except per share amounts)



As of December 31,


2020


2019

ASSETS




Current assets:




Cash and equivalents

$

888.9



$

211.2


Trade accounts receivable, less allowance for credit losses of $37.1 and $22.8,
respectively

361.0



443.6


Inventories, net

266.9



277.9


Prepaid expenses and other current assets

73.7



69.2


Total current assets

1,590.5



1,001.9


Property, plant and equipment, net

303.0



290.3


Operating lease right-of-use assets

165.3



200.1


Other long-term assets

127.3



74.4


Goodwill

3,430.7



3,306.0


Other intangible assets, net

1,259.2



1,285.6


Total assets

$

6,876.0



$

6,158.3


LIABILITIES AND EQUITY




Current liabilities:




Short-term debt

$

886.8



$

3.9


Trade accounts payable

235.1



208.0


Accrued expenses and other liabilities

530.3



470.6


Operating lease liabilities

32.5



26.7


Total current liabilities

1,684.7



709.2


Operating lease liabilities

153.8



186.0


Other long-term liabilities

408.8



399.3


Long-term debt

907.7



1,321.0


Commitments and contingencies




Stockholders' equity:




Preferred stock, no par value, 15.0 million shares authorized; no shares issued or
outstanding at December 31, 2020 and December 31, 2019




Common stock - $0.01 par value, 500.0 million shares authorized; 160.2 million shares
issued and 160.0 million shares outstanding at December 31, 2020; 158.7 million shares
issued and outstanding at December 31, 2019

1.6



1.6


Additional paid-in capital

3,684.4



3,589.7


Retained earnings

126.4



93.1


Accumulated other comprehensive loss

(91.8)



(144.2)


Total Envista stockholders' equity

3,720.6



3,540.2


Noncontrolling interests

0.4



2.6


Total stockholders' equity

3,721.0



3,542.8


Total liabilities and stockholders' equity

$

6,876.0



$

6,158.3


 

ENVISTA HOLDINGS CORPORATION
CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED)
($ in millions)



Year Ended December 31,


2020


2019


2018

Cash flows from operating activities:






Net income

$

33.3



$

217.6



$

230.7


Noncash items:






Depreciation

42.4



39.0



39.4


Amortization

90.2



89.5



90.6


Allowance for credit losses

23.0



9.5



4.7


Stock-based compensation expense

22.6



18.4



13.3


Restructuring charges

11.1






Impairment charges

32.6





0.4


Amortization of right-of-use assets

30.5



39.6




Amortization of debt discount and issuance costs

13.4






Change in deferred income taxes

(91.4)



(8.9)



1.7


Change in trade accounts receivable

71.9



3.3



(8.5)


Change in inventories

11.9



(1.5)



(8.9)


Change in trade accounts payable

21.6



(7.9)



(3.8)


Change in prepaid expenses and other assets

(2.5)



(8.6)



13.8


Change in accrued expenses and other liabilities

10.0



44.5



26.7


Change in operating lease liabilities

(36.7)



(37.0)




Net cash provided by operating activities

283.9



397.5



400.1


Cash flows from investing activities:






Acquisitions, net of cash acquired

(40.7)






Payments for additions to property, plant and equipment

(47.7)



(77.8)



(72.2)


Proceeds from sales of property, plant and equipment

5.3



1.6




All other investing activities

14.0



(2.2)



(3.3)


Net cash used in investing activities

(69.1)



(78.4)



(75.5)


Cash flows from financing activities:






Proceeds from issuance of convertible senior notes

517.5






Payment of debt issuance and other deferred financing costs

(17.2)



(2.4)




Proceeds from revolving line of credit

249.8






Repayment of revolving line of credit

(250.0)






Proceeds from borrowings



1,318.3




Repayment of borrowings



(0.3)




Purchase of capped calls related to issuance of convertible senior notes

(20.7)






Proceeds from stock option exercises

13.8






Proceeds from the public offering of common stock, net of issuance
costs



643.4




Consideration to Former Parent in connection with the Separation



(1,950.0)




Net transfers to Former Parent



(116.5)



(324.6)


All other financing activities

(0.7)



(0.2)




Net cash "provided by" (used in) financing activities

492.5



(107.7)



(324.6)


Effect of exchange rate changes on cash and equivalents

(29.6)



(0.2)




Net change in cash and equivalents

677.7



211.2




Beginning balance of cash and equivalents

211.2






Ending balance of cash and equivalents

$

888.9



$

211.2



$


 

ENVISTA HOLDINGS CORPORATION
SEGMENT INFORMATION (UNAUDITED)
($ in millions)



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Sales








Specialty Products & Technologies

$

343.2



$

328.8



$

1,117.3



$

1,342.7


Equipment & Consumables

389.1



391.7



1,164.7



1,408.9


Total

$

732.3



$

720.5



$

2,282.0



$

2,751.6










Operating Profit (Loss)








Specialty Products & Technologies

$

40.9



$

52.4



$

72.7



$

227.7


Equipment & Consumables

66.3



57.7



38.2



105.8


Other

(10.4)



(32.1)



(77.6)



(56.0)


Total

$

96.8



$

78.0



$

33.3



$

277.5










Operating Margin








Specialty Products & Technologies

11.9

%


15.9

%


6.5

%


17.0

%

Equipment & Consumables

17.0

%


14.7

%


3.3

%


7.5

%

Total

13.2

%


10.8

%


1.5

%


10.1

%

 

ENVISTA HOLDINGS CORPORATION
SUMMARY OF FINANCIAL METRICS (UNAUDITED)
($ and shares in millions, except per share amounts)



GAAP



NON-GAAP *


Three Months Ended



Three Months Ended


December 31, 2020


December 31, 2019



December 31, 2020


December 31, 2019

Gross Profit

$

388.5



$

389.4



Adjusted Gross Profit

$

398.1



$

389.4


Operating Profit

$

96.8



$

78.0



Adjusted Operating
Profit

$

141.2



$

113.4


Net Income

$

108.4



$

56.1



Adjusted Net Income

$

94.6



$

84.8


Diluted EPS

$

0.64



$

0.35



Adjusted Diluted EPS

$

0.56



$

0.52


Diluted Shares

170.0



159.3



Adjusted Diluted
Shares

170.0



162.3


N/A





Adjusted EBITDA

$

150.8



$

122.5


Sales Growth

1.6

%


(5.0)

%


Core Sales Growth

3.4

%


(3.5)

%

Operating Cash Flow

$

193.4



$

187.0



Free Cash Flow

$

185.6



$

171.1



* For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. See also the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures."

 

ENVISTA HOLDINGS CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)
($ in millions)


Adjusted Gross Profit and Adjusted Gross Margin



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Gross Profit

$

388.5



$

389.4



$

1,158.1



$

1,513.1


Restructuring costs and asset impairments A

9.6





44.9




Adjusted Gross Profit

$

398.1



$

389.4



$

1,203.0



$

1,513.1










Gross Margin (Gross Profit / Sales)

53.1

%


54.0

%


50.7

%


55.0

%

Adjusted Gross Margin (Adjusted Gross Profit /
Sales)

54.4

%


54.0

%


52.7

%


55.0

%



Adjusted Operating Profit



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Consolidated








Operating Profit

$

96.8



$

78.0



$

33.3



$

277.5


Amortization of acquisition-related intangible
assets

22.2



22.2



90.2



89.5


Restructuring costs and asset impairments A

35.5





135.4




Contingent loss reserve B

(13.3)



9.0



2.7



9.0


Separation costs C



4.2





4.2


Adjusted Operating Profit

$

141.2



$

113.4



$

261.6



$

380.2


Adjusted Operating Profit as a % of Sales

19.3

%


15.7

%


11.5

%


13.8

%









Specialty Products & Technologies








Operating Profit

$

40.9



$

52.4



$

72.7



$

227.7


Amortization of acquisition-related intangible
assets

15.2



14.3



60.0



57.7


Restructuring costs and asset impairments A

15.8





43.8




Adjusted Operating Profit

$

71.9



$

66.7



$

176.5



$

285.4


Adjusted Operating Profit as a % of Sales

20.9

%


20.3

%


15.8

%


21.3

%









Equipment & Consumables








Operating Profit

$

66.3



$

57.7



$

38.2



$

105.8


Amortization of acquisition-related intangible
assets

7.0



7.9



30.2



31.8


Restructuring costs and asset impairments A

19.3





85.6




Adjusted Operating Profit

$

92.6



$

65.6



$

154.0



$

137.6


Adjusted Operating Profit as a % of Sales

23.8

%


16.7

%


13.2

%


9.8

%


See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures



Adjusted Net Income



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Net Income

$

108.4



$

56.1



$

33.3



$

217.6


Pretax amortization of acquisition-related
intangible assets

22.2



22.2



90.2



89.5


Restructuring costs and asset impairments A

35.5





135.4




Contingent loss reserve B

(13.3)



9.0



2.7



9.0


Separation costs C



4.2





4.2


Non-cash interest expense - convertible senior
notes D

4.6





11.0




Tax effect of adjustments reflected above E

(10.8)



(8.0)



(56.9)



(23.8)


Discrete tax adjustments and other tax-related
adjustments F

(52.0)



1.3



(54.6)



(6.5)


Adjusted Net Income

$

94.6



$

84.8



$

161.1



$

290.0




Adjusted Diluted Earnings Per Share



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Diluted Earnings Per Share

$

0.64



$

0.35



$

0.20



$

1.60


Pretax amortization of acquisition-related
intangible assets

0.13



0.14



0.55



0.55


Restructuring costs and asset impairments A

0.21





0.83




Contingent loss reserve B

(0.08)



0.06



0.02



0.06


Separation costs C



0.03





0.03


Non-cash interest expense - convertible senior
notes D

0.03





0.07




Tax effect of adjustments reflected above E

(0.06)



(0.06)



(0.35)



(0.15)


Discrete tax adjustments and other tax-related
adjustments F

(0.31)



0.01



(0.34)



(0.04)


Dilutive impact of IPO and conversion shares G



(0.01)





(0.26)


Adjusted Diluted Earnings Per Share

$

0.56



$

0.52



$

0.98



$

1.79


 

Adjusted Diluted Shares Outstanding



Three Months Ended


Year Ended

(shares in millions)

December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Average common stock shares outstanding - diluted

170.0



159.3



164.1



136.4


Dilutive impact of IPO and conversion shares G



3.0





25.9


Average common stock and common stock
equivalent shares outstanding - diluted

170.0



162.3



164.1



162.3



See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

Adjusted EBITDA



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Net Income

$

108.4



$

56.1



$

33.3



$

217.6


Interest expense, net

21.3



3.3



62.5



3.5


Income taxes

(34.2)



18.5



(63.4)



57.9


Depreciation

10.9



9.2



42.4



39.0


Amortization of acquisition-related intangible
assets

22.2



22.2



90.2



89.5


Restructuring costs and asset impairments A

35.5





135.4




Contingent loss reserve B

(13.3)



9.0



2.7



9.0


Separation costs C



4.2





4.2


Adjusted EBITDA

$

150.8



$

122.5



$

303.1



$

420.7



See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

Core Sales Growth 1


Consolidated

% Change Three Month
Period Ended

December 31, 2020 vs.
Comparable 2019 Period


% Change Year Ended

December 31, 2020 vs.
Comparable 2019 Period

Total sales growth

1.6

%


(17.1)

%

Less the impact of:




Acquisitions

(0.1)

%


(0.2)

%

Discontinued products

3.8

%


2.2

%

Currency exchange rates

(1.9)

%


0.3

%

Core sales growth

3.4

%


(14.8)

%





Specialty Products & Technologies




Total sales growth

4.4

%


(16.8)

%

Less the impact of:




Acquisitions

(0.2)

%


(0.3)

%

Discontinued products

0.3

%


0.6

%

Currency exchange rates

(2.3)

%


(0.1)

%

Core sales growth

2.2

%


(16.6)

%





Equipment & Consumables




Total sales growth

(0.7)

%


(17.3)

%

Less the impact of:




Discontinued products

6.7

%


3.8

%

Currency exchange rates

(1.7)

%


0.3

%

Core sales growth

4.3

%


(13.2)

%


1  

We use the term "core sales" to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term "core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

 

Reconciliation of Operating Cash Flows to Free Cash Flow



Three Months Ended


Year Ended


December 31, 2020


December 31, 2019


December 31, 2020


December 31, 2019

Net Operating Cash Used in Investing Activities

$

(5.1)



$

(15.8)



$

(69.1)



$

(78.4)


Net Operating Cash Provided by (Used in)
Financing Activities

$

3.8



$

(148.1)



$

492.5



$

(107.7)










Net Operating Cash Provided by Operating
Activities

$

193.4



$

187.0



$

283.9



$

397.5


Less: payments for additions to property, plant
and equipment (capital expenditures)

(13.1)



(15.9)



(47.7)



(77.8)


Plus: proceeds from sales of property, plant and
equipment (capital disposals)

5.3





5.3



1.6


Free Cash Flow

$

185.6



$

171.1



$

241.5



$

321.3










Net Income

$

108.4



$

56.1



$

33.0



$

217.6


Free Cash Flow to Net Income Conversion Ratio

1.71



3.05



7.32



1.48



See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 

ENVISTA HOLDINGS CORPORATION

NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)


A 

We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Envista Business System. These restructuring plans are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period.



B

Represents an accrual adjustment for a significant legal matter.



C 

On December 18, 2019, Danaher Corporation ("Danaher") completed the split-off exchange offer of all the common shares of Envista Holdings Corporation ("Envista" or (the "Company") held by Danaher in exchange for shares of Danaher common stock. This line item primarily reflects legal and professional services costs incurred in connection with this transaction.



D 

Non-cash interest expense represents accretion of the debt discount associated with the convertible senior notes due 2025.



E 

This line item reflects the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.



F 

The discrete tax matters relate primarily to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets. During 2020 we recorded a one-time income tax benefit of approximately $59.0 million related primarily to the recognition of a deferred tax asset associated with the estimated amortizable value of a tax basis step-up of the Company's Switzerland assets.



G 

In connection with the initial public offering ("IPO"), an additional 30.8 million shares were issued on September 20, 2019. This line item reflects the dilutive impact of these IPO shares as if outstanding as of the beginning of each period presented. In addition, certain Envista employees were previously granted Danaher equity awards. On December 18, 2019, Danaher completed the split-off exchange offer of all the common shares of Envista held by Danaher in exchange for shares of Danaher common stock. As a result, the equity awards held by certain Envista employees to purchase Danaher shares have been converted into equity awards to purchase Envista's shares. The dilutive impact of these equity awards are included in this line item to reflect the potential dilution as if outstanding as of the beginning of each period presented.

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista's results that, when reconciled to the corresponding GAAP measure, help our investors to:

  • with respect to Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista's business and compare Envista's profitability to prior and future periods and to Envista's peers;
  • with respect to Adjusted Diluted Earnings Per Share, provide investors with improved comparability for Adjusted Diluted EPS as share counts under GAAP are calculated using a weighted average approach;
  • with respect to Adjusted Diluted Shares Outstanding, allows for the impact of the IPO shares and dilution related to the conversion of Danaher equity awards into Envista equity awards to be presented as if they were outstanding for all prior periods presented and for the dilutive impact of stock options and restricted stock units;
  • with respect to Core Sales, identify underlying growth trends in Envista's business and compare Envista's revenue performance with prior and future periods and to Envista's peers;
  • with respect to Adjusted EBITDA, help investors understand operational factors associated with a company's financial performance because it excludes the following from consideration: interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts. In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and
  • with respect to Free Cash Flow (the "FCF Measure"), understand Envista's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).

Management uses these non-GAAP measures to measure the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

  • With respect to Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA:
    • We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. We do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly-acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
    • We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Envista Business System. These restructuring plans are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period.
    • With respect to the other items excluded from Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
  • With respect to core sales, we exclude (1) the effect of acquisitions because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends.
  • With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

 

SOURCE Envista Holdings Corporation


Sign up and never miss an investor alert.

Sign up and never miss an investor alert.